**Acknowledgement**

To CAPES for the fellowship to Marques-Marinho FD, to Lima AA and Reis IA for the important initial collaboration.

## **5. References**


<sup>\*</sup> Corresponding Author

[6] da Costa PQ, Rey LC, Coelho HL. Lack of Drug Preparations for Use in Children in Brazil. J. Pediatr. 2009;85(3): 229-35.

Cellulose and Its Derivatives Use in the Pharmaceutical Compounding Practice 159

[25] Wada M, Chanzy H, Nishiyama Y, Langan P. Cellulose IIII Crystal Structure and Hydrogen Bonding by Synchrotron X-ray and Neutron Fiber Diffraction.

[26] Ishikawa A, Okano T, Sugiyama J. Fine Structure and Tensile Properties of Ramie Fibres in the Crystalline Form of Cellulose I, II, Illl and IVI. Polymer 1997;38(2): 463-8. [27] United States Pharmacopeial Convention. The United States Pharmacopeia-National

[28] Béchard SR, Levy L, Clas SD. Thermal, Mechanical and Functional Properties of Cellulose Acetate Phthalate (CAP) Coatings Obtained from Neutralized Aqueous

[29] Prista LN, Alves AC, Morgado R, Lobo JS. Tecnologia Farmacêutica. Lisboa: Fundação

[30] Prista LN, Alves AC, Morgado R. Tecnologia Farmacêutica. Lisboa: Fundação Calouste

[31] Marques-marinho FD, Vianna-soares CD, Carmo VA, Campos LM. Avaliação da Qualidade de Pantoprazol Cápsulas Manipuladas Gastro-Resistentes. Lat. Am. J.

[32] dos Santos L, Guterres SS, Bergold AM. Preparação e Avaliação de Cápsulas Gastro-

[33] Ferreira AO, Holandino C. Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting. Int. J. Pharm. Compound. 2008;12(2):

[34] Webster KD, Al-achi A, Greenwood R. In Vitro Studies on the Release of Morphine Sulfate from Compounded Slow-Release Morphine-Sulfate Capsules. Int. J. Pharm.

[35] Bogner RH, Szwejkowski J, Houston A. Release of Morphine Sulfate from Compounded Slow Release Capsules: the Effect of Formulation on Release. Int. J. Pharm. Compound.

[36] Timmons ED, Timmons SP. Custom-Compounded Micronized Hormones in a Slow-

[37] Glowiak DL, Green JL, Bowman BJ. In Vitro Evaluation of Extemporaneously Compounded Slow-Release Capsules Containing Morphine Sulfate or Oxycodone

[38] Pinheiro VA, Kaneko TM, Velasco MV, Consiglieri VO. Development and In Vitro Evaluation of Extended-Release Theophylline Matrix Capsules. Braz. J. Pharm. Sci.

[39] Ojantakanen S, Marvola M, Hannula AM, Klinge E, Naukkarinnen T. Bioavailability of Ibuprofen from Hard Gelatin Capsules Containing Different Viscosity Grades of Hydroxypropylmethylcellulose and Sodium Carboxymethylcellulose. Eur. J. Pharm.

[40] Ojantakanen S. Effect of Viscosity Grade of Polymer Additive and Compression Force on Dissolution of Ibuprofen from Hard Gelatin Capsules. Acta Pharm. Fennica

Release Capsule Matrix. Int. J. Pharm. Compound. 2002;6(5): 378-9.

Hydrochloride. Int. J. Pharm. Compound. 2005;9(2): 157-64.

Resistentes de Diclofenaco de Sódio. Lat. Am. J. Pharm. 2007;26(3): 355-61.

FormularyRockville: United States Pharmacopeia; 2011. p. 1416-19.

Macromolecules 2004;37: 8548-55.

Solutions. Int. J. Pharm. 1995;114(2): 205-13.

Calouste Gulbekian; 2002. p. 562-7.

Gulbekian; 1995. p. 2027-8.

Pharm. 2009;28(6): 899-906.

Compound. 1999;3(5): 409-11.

163-9.

2001;5(5): 401-5.

2007;43(2): 253-61.

Sci. 1993;1: 109-14.

1992;101(33): 119-26.


[25] Wada M, Chanzy H, Nishiyama Y, Langan P. Cellulose IIII Crystal Structure and Hydrogen Bonding by Synchrotron X-ray and Neutron Fiber Diffraction. Macromolecules 2004;37: 8548-55.

158 Cellulose – Medical, Pharmaceutical and Electronic Applications

Brazil. J. Pediatr. 2009;85(3): 229-35.

Other? Pharm. World Sci. 2007;29: 526-33.

London: Pharmaceutical Press; 2009.

Berlin:Springer-Verlag. 1990; 20-39.

Carbohydr. Res. 1988;180: 345-50.

Concepts. Ann. Bot. 2005;96: 9-21.

Washington: American Pharmacists Association; 2008.

J. Pharm. 2005;300: 56-66.

2112-9.

1999;54: 1-14.

3101-6.

Sci. 2006;9(3): 398-426.

[6] da Costa PQ, Rey LC, Coelho HL. Lack of Drug Preparations for Use in Children in

[7] Nahata MC, Allen LV Jr. Extemporaneous Drug Formulations. Clin. Ther. 2008;30(11):

[8] Standing JF, Tuleu C. Paediatric Formulations- Getting to the Heart of the Problem. Int.

[9] Prot-labarthe S, Bussières JF, Brion F, Bourdon O. Comparison of Hospital Pharmacy Practice in France and Canada: Can Different Practice Perspectives Complement each

[10] Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr. 2003;92: 486-490. [11] Allen LV Jr. The Art, Science, and Technology of Pharmaceutical Compounding.

[12] Rowe RC, Sheskey PJ, Quinn ME., editors. Handbook of Pharmaceutical Excipients.

[13] Pifferi G, Santoro P, Pedrani M. Quality and functionality of excipients. Il Farmaco

[14] Glass BD, Haywood A. Stability Considerations in Liquid Dosage Forms Extemporaneously Prepared from Commercially Available Products. J. Pharm. Pharm.

[16] Kamel S, Ali N, Jahangir K, Shah SM, El-Gendy AA. Pharmaceutical Significance of

[17] Nobles D, Romanovicz DK, Brown RM Jr. Cellulose in Cyanobacteria. Origin of

[18] Brown RM Jr. Algae as Tools in Studying the Biosynthesis of Cellulose Nature's Most Abundant Macromolecule. In Wiessner G, Robinson DG, Starr RC, editors. Experimental Phycology. Cell Walls and Surfaces, Reproduction, Photosynthesis.

[19] Kimura S, Itoh T. A New Cellulosic Structure, the Tunic Cord in the Ascidian

[20] Brown RM Jr. Cellulose Structure and Biosynthesis: What is in Store for the 21 st

[21] Klemm D, Heublein B, Fink HP, Bohn A. Cellulose: Fascinating Biopolymer and

[22] Weimer PJ, French AD, Calamari TA Jr. Differential Fermentation of Cellulose Allomorphs by Ruminal Cellulolytic Bacteria. Appl. Environ. Microbiol. 1991;57(11):

[23] Kuga S, Brown RM Jr. Silver Labeling of the Reducing Ends of Bacterial Cellulose.

[24] Saxena IM, Brown RM Jr. Cellulose Biosynthesis: Current Views and Evolving

[15] Edgar K J. Cellulose Esters in Drug Delivery. Cellulose 2007;14(1): 49-64.

Cellulose- A Review. eXPRESS Polymer Letters 2008;2(11): 758-78.

Vascular Plant Cellulose Synthase? Plant Physiol. 2001;127: 529-42.

Polyandrocarpa misakiensis. Protoplasma 1998;204: 94-102.

Sustainable Raw Material. Angew. Chem. Int. Ed. 2005;44: 3358-93.

Century? J. Polym. Sci. A Polym. Chem. 2004;42: 487-95.

	- [41] United States Pharmacopeial Convention. USP pharmacists´ pharmacopeia Rockville: United States Pharmacopeia; 2008. p. 333.

Cellulose and Its Derivatives Use in the Pharmaceutical Compounding Practice 161

[58] Nahata MC, Morosco RS, Trowbridge JM. Stability of Dapsone in Two Oral Liquid

[59] Johnson CE, Wagner DS, Bussard WE. Stability of Dolasetron in Two Oral Liquid

[60] Dentinger PJ, Swenson CF, Anaizi NH. Stability of Famotidine in an Extemporaneously

[61] Allen LV Jr, Erickson MA 3rd. Stability of Ketoconazole, Metolazone, Metronidazole, Procainamide Hydrochloride and Spironolactone in Extemporaneously Compounded

[62] Allen LV Jr, Erickson MA 3rd. Stability of Labetalol Hydrochloride, Metoprolol Tartrate, Verapamil Hydrochloride, and Spironolactone with Hydrochlorothiazide in Extemporaneously Compounded Oral Liquids. Am. J. Health Syst. Pharm. 1996;53(19):

[63] Nahata MC, Morosco RS, Hipple TF. Stability of Lamotrigine in Two Extemporaneously Prepared Oral Suspensions at 4 and 25 Degrees C. Am. J. Health Syst. Pharm.

[64] Nahata MC, Morosco RS, Leguire LE. Development of Two Stable Oral Suspensions of Levodopa-Carbidopa for Children with Amblyopia. J. Pediatr. Ophthalmol. Strabismus.

[65] VandenBussche HL, Johnson CE, Fontana EM, Meram JM. Stability of Levofloxacin in an Extemporaneously Compounded Oral Liquid. Am. J. Health Syst. Pharm. 1999;

[66] Hutchinson DJ, Johnson CE, Klein KC. Stability of Extemporaneously Prepared

[68] Zhang YP, Trissel LA, Fox JL. Naratriptan Hydrochloride in Extemporaneously

[69] Johnson CE, Price J, Hession JM. Stability of Norfloxacin in an Extemporaneously

[70] Haslam JL, Egodage KL, Chen Y, Rajewski RA, Stella V. Stability of Rifabutin in Two Extemporaneously Compounded Oral Liquids. Am. J. Health Syst. Pharm. 1999;56(4):

[71] Nahata MC, Morosco RS, Hipple TF. Stability of Spironolactone in an Extemporaneously Prepared Suspension at Two Temperatures. Ann. Pharmacother.

[72] Navid F, Christensen R, Minkin P, Stewart CF, Furman WL, Baker S. Stability of

[73] Jacobson PA, Johnson CE, West NJ, Foster JA. Stability of Tacrolimus in an Extemporaneously Compounded Oral Liquid. Am. J. Health Syst. Pharm. 1997;54(2):

Moxifloxacin Oral Suspensions. Am. J. Health Syst. Pharm. 2009;66(7): 665-7. [67] Ensom MH. Stability of Mycophenolate Mofetil in a 1:1 Mixture of Ora-Sweet and Ora-

Compounded Oral Suspensions. Int. J. Pharm. Compound. 2000;4(1): 69-71.

Prepared Oral Liquid. Am. J. Health Syst. Pharm. 2001;58: 577-9.

Sunitinib in Oral Suspension. Ann. Pharmacother. 2008;42(7): 962-6.

Compounded Oral Liquid. Am. J. Health Syst. Pharm. 2000;57(14): 1340-2.

Dosage Forms. Ann. Pharmacother. 2000;34(7): 848-50.

Vehicles. Am. J. Health Syst. Pharm. 2003;60(21): 2242-4.

Oral Liquids. Am. J. Health Syst. Pharm. 1996;53(17): 2073-8.

2304-9.

1999;56(3): 240-2.

2000;37(6): 333-7.

56(22): 2316-8.

333-6.

178-80.

1993; 27(10): 1198-9.

Plus. Can. J. Hosp. Pharm. 2002;55(1): 63-5.


[58] Nahata MC, Morosco RS, Trowbridge JM. Stability of Dapsone in Two Oral Liquid Dosage Forms. Ann. Pharmacother. 2000;34(7): 848-50.

160 Cellulose – Medical, Pharmaceutical and Electronic Applications

United States Pharmacopeia; 2008. p. 333.

Compound. 1997;6(5): 378-9.

Neurol. 1999;2(3): 195-7.

Pharm. 2000;57(12): 1141-3.

Syst. Pharm. 2006;63(3): 254-7.

Pharm. Compound. 2005;9(5): 402-6.

Health Syst. Pharm. 2003;60(1): 75-7.

Health Syst. Pharm. 1996;53(16): 1944-9.

Am. J. Health Syst. Pharm. 1995;52(14): 1558-60.

Temperatures. Ann. Pharmacother. 2003;37(4): 506-9.

1720-4.

[41] United States Pharmacopeial Convention. USP pharmacists´ pharmacopeia Rockville:

[42] Roy JJ, Besner JG. Stability of Clonazepam Suspension in HSC Vehicle. Int. J. Pharm.

[43] Nahata MC. Development of Two Stable Oral Suspensions for Gabapentin. Pediatr.

[44] Nahata MC, Morosco RS, Willhite, EA. Stability of Nifedipine in Two Oral Suspensions

[45] Metras JI, Swenson CF, Mcdermott MP. Stability of Procainamide Hydrochloride in an Extemporaneously Compounded Oral Liquid. Am. J. Health Syst. Pharm. 1992;49(7):

[46] Nahata MC, Morosco RS, Trowbridge JM. Stability of Propylthiouracil in Extemporaneously Prepared Oral Suspensions at 4 and 25 °C. Am. J. Health Syst.

[47] Nahata MC, Morosco RS, Peritore SP. Stability of Pyrazinamide in Two Suspensions.

[48] Nahata MC, Morosco RS, Hipple TF. Stability of Pyrimethamine in a Liquid Dosage Formulation Stored for Three Months. Am. J. Health Syst. Pharm. 1997;54(23): 2714-6. [49] Nahata MC, Morosco RS, Brady MT. Extemporaneous Sildenafil Citrate Oral Suspensions for the Treatment of Pulmonary Hypertension in Children. Am. J. Health

[50] Sidhom MB, Rivera N, Almoazen H, Taft DR, Kirschenbaum HL. Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations. Int. J.

[51] Nahata MC, Morosco RS. Stability of Sotalol in Two Liquid Formulations at Two

[52] Nahata MC, Morosco RS. Stability of Tiagabine in Two Oral Liquid Vehicles. Am. J.

[53] Alexander KS, Haribhakti RP, Parker GA. Stability of Acetazolamide in Suspension

[54] Allen LV Jr, Erickson MA 3rd. Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids. Am. J.

[55] Allen LV Jr, Erickson MA 3rd. Stability of Alprazolam, Chloroquine Phosphate, Cisapride, Enalapril Maleate, and Hydralazine Hydrochloride in Extemporaneously

[56] Allen LV Jr, Erickson MA 3rd. Stability of Baclofen, Captopril, Diltiazem Hydrochloride, Dipyridamole, and Flecainide Acetate in Extemporaneously

[57] Allen LV Jr, Erickson MA 3rd. Stability of Bethanechol Chloride, Pyrazinamide, Quinidine Sulfate, Rifampin, and Tetracycline Hydrochloride in Extemporaneously

Compounded from Tablets. Am. J. Hosp. Pharm. 1991;48(6): 1241-4.

Compounded Oral Liquids. Am. J. Health Syst. Pharm. 1998;55: 1915-20.

Compounded Oral Liquids. Am. J. Health Syst. Pharm. 1996;53(18): 2179-84.

Compounded Oral Liquids. Am. J. Health Syst. Pharm. 1998;55(17), 1804-9.

Stored at Two Temperatures. J. Am. Pharm. Assoc. 2002; 42(6): 865-7.

	- [74] Han J, Beeton A, Long PF, Wong I, Tuleu C. Physical and Microbiological Stability of an Extemporaneous Tacrolimus Suspension for Paediatric Use. J. Clin. Pharm. Ther. 2006;31(2): 167-72.

**Chapter 9** 

© 2013 Kleinschek et al., licensee InTech. This is an open access chapter distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2013 Kleinschek et al., licensee InTech. This is a paper distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Plasma Induced Hydrophilic Cellulose Wound** 

The wound care industry is a highly diverse and competitive arena - including standard products such as dry bandages to sophisticated hydrogels and alginate dressings, and encompassing artificial skin and anti-infective used in wound care. A broad range of available modern dressings composed of layers possessing specific functionality has been placed on the market. Waddings and gauzes were replaced by new natural, synthetic and semi-synthetic biomaterials, which depending on their physical, chemical and technological properties are capable to absorb the exudate excess by maintaining the proper moisture environment on/in the wound. The use of textiles in medicine has a long tradition; specially

Cellulose and its derivatives are very often used as a functional part of different wound dressing material e.g. as hydrogels, fibre, non-woven. Cellulose micro-fibrillar structure control the accessibility of the surface, while the bulk polar groups (-OH groups) ensure an attraction of the water molecule to the cellulose fibre (hydrogen bonds). Generally different standard chemical pre-treatments (i.e. alkaline washing, bleaching, and slack-mercerization) are used to improve the sorption capacity [1-4], but besides the ecological pollution, they also worsen fibres mechanical properties to a large extent. On the subject of the latter, plasma treatments are known to be rather harmless surface activation procedures leading to enhancement of hydrophilic properties; the best results are obtained using highly nonequilibrium oxygen plasma. Reactive particles created in plasma readily interact with cellulose resulting in formation of surface functional groups, as well as etching. The properties of plasma treated materials depend on the processing parameters and are measured using surface sensitive techniques. Numerous authors worldwide addressed modification of cellulose and other suitable materials by gaseous plasma treatment [5-16].

Zdenka Persin, Miran Mozetic, Alenka Vesel, Tina Maver,

Uros Maver and Karin Stana Kleinschek

Additional information is available at the end of the chapter

**Dressing** 

http://dx.doi.org/10.5772/55867

woven textiles are mostly used.

**1. Introduction** 

